Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, T. Articles by King, A. M. Q. Search for Related Content PubMed PubMed Citation Articles by Jackson, T. Articles by King, A. M. Q.

Next Article 

Journal of Virology, February 2002, p. 935-941, Vol. 76, No. 3
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.3.935-941.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Integrin vß1 Is a Receptor for Foot-and-Mouth Disease Virus

Terry Jackson,^1* A. Paul Mould,² Dean Sheppard,³ and Andrew M. Q. King¹

Department of Molecular Biology, Institute for Animal Health, Pirbright, Surrey GU24 ONF,¹ Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom,² Lung Biology Center, Cardiovascular Research Institute, Department of Medicine, University of California, San Francisco, California 94143-0854³

Received 30 July 2001/ Accepted 30 October 2001

Top Abstract Introduction Materials and Methods Results Discussion References

 
Infection by field strains of Foot-and-mouth disease virus (FMDV) is initiated by binding to certain species of arginine-glycine-aspartic acid (RGD)-dependent integrin including vß3 and the epithelial integrin vß6. In this report we show that the integrin vß1, when expressed as a human/hamster heterodimer on transfected CHOB2 cells, is a receptor for FMDV. Virus binding and infection mediated by vß1 was inefficient in the presence of physiological concentrations of calcium and magnesium but were significantly enhanced by reagents that activate the integrin and promote ligand binding. The ability of chimeric 5/v integrin subunits, in association with the ß1 chain, to bind FMDV and mediate infection matched the ligand binding specificity of vß1, not 5ß1, thus providing further evidence for the receptor role of vß1. In addition, data are presented suggesting that amino acid residues near the RGD motif may be important for differentiating between the binding specificities of vß1 and vß6.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Field strains of Foot-and-mouth disease virus (FMDV), the type species of the Aphthovirus genus of the Picornaviridae (3), infects cells by attaching to integrin receptors through a long surface loop, the GH loop of VP1 (22, 23, 24, 30, 33). The sequence of this loop contains a conserved tripeptide, arginine-glycine-aspartic acid (RGD), which is characteristic of the ligands of several members of the integrin family (20, 50). Integrins are cell surface /ß heterodimeric glycoproteins that contribute to a variety of functions, including cell-cell and cell-matrix adhesion and induction of signal transduction pathways (14, 16, 19, 20, 61).

A general property of integrins is that they exist in at least two conformations, active (competent to bind ligand) and inactive (unable to bind ligand) (50). Conversion from an inactive to an active state (integrin activation) is postulated to occur through two different mechanisms, collectively referred to as "inside-out signaling"; the first, avidity modulation, is mediated by clustering of heterodimers at the cell surface, whereas the second, affinity modulation, is mediated through conformational changes in the integrin ectodomain. Although the molecular mechanisms that regulate inside-out signaling in vivo remain unclear (14, 16, 19, 61), the conformational changes that occur naturally in the extracellular domains upon integrin activation can be induced experimentally by activating anti-integrin antibodies. These promote ligand binding by stabilizing epitopes that are expressed only on the active conformation (2, 39). The affinity of integrins for their ligands is also regulated by divalent cations (25, 37) and, in general, ligand binding is maximal in the presence of manganese ions, which are believed to stabilize shapes of the ligand binding pocket that favor ligand binding (27, 29).

Several viruses have been reported to utilize RGD-dependent integrins to initiate infection. Adenovirus has been shown to use vß3, vß5, and vß1 (28, 55, 56), and human parechovirus type 1 uses vß3 and vß1 (44, 52), whereas coxsackievirus A9 has been shown to use vß3 (45). In addition, vß1, vß3, and 5ß1 have been implicated as receptors for coxsackievirus A9, the Barty strain of echovirus type 9, and adenovirus, respectively (13, 43, 44).

Since the various RGD-binding integrins have distinct tissue distributions, it is important to establish which species have the potential to act as receptors for FMDV. Prior to these studies, FMDV was reported to use two RGD-dependent integrins, vß3 and vß6, to initiate infection of cultured cells (4, 24), whereas the evidence for two other integrins, 5ß1 and vß5, has been consistently negative (24, 32, 42). A fifth candidate integrin, vß1, has been difficult to study since its expression appears restricted in a cell-specific manner, as several cell types express both subunits in excess but do not appear to express this heterodimer (49, 53). In this report, we show that CHOB2 cells, which are normally nonpermissive for field strains of FMDV, become susceptible to infection after transfection with the integrin v subunit, and we show by various criteria that this susceptibility is due to the expression of vß1 at the cell surface. Furthermore, we show that virus binding and infection mediated by vß1 are greatly enhanced in the presence of reagents that activate the integrin and promote ligand binding.

In addition, data are presented suggesting that amino acid residues near the RGD motif may be important for differentiating between the binding specificities of vß1 and vß6.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cells and viruses. Baby hamster kidney (BHK) cells, the 5-deficient Chinese hamster ovary (CHO) variant cell line CHOB2 (48), and stably transfected CHOB2 cell lines expressing vß6 (CHOB2-vß6) (54), vß1 (CHOB2-vß1) (38), or v/5 chimeras in association with the ß1 subunit [v/5(F1-G232) and 5/v(F1-G223), discussed in reference 38] were cultivated as described previously. The v/5(F1-G232) chimera consists of residues 1 to 232 of 5 followed by residue 224 of v onwards and has an identical ligand binding specificity to wt (wild-type) 5ß1 (38). The 5/v(F1-G223) chimera consists of residues 1 to 223 of v followed by residue 233 of 5 onwards and has a ligand binding specificity identical to that of wt vß1 (38). Virus stocks of the FMDV strains, O1Kcad² and O1BFS, were prepared with primary bovine thyroid and BHK cells, respectively (24). The multiplicity of infection (MOI) (PFU per cell) values for both FMDV strains were based on the virus titer on BHK cells. Purification of FMDV was carried out as described previously (11).

Antibodies, peptides, and reagents. The GRGDSP and GRGESP peptides were purchased from Novabiochem. The FMDV VP1 GH loop peptide [FMDV-RGD (VPNLRGDLQVLA)], and the control RGE version (FMDV-RGE) were prepared as described previously (23). The anti-integrin monoclonal antibodies (MAbs) used in these studies were the functional blocking MAbs P1F6 (anti-vß5) and 10D5 (anti-vß6) from Chemicon, L230 (anti-v), and the activating anti-ß1 MAb 9EG7 (rat immunoglobulin G [IgG]) (2). The mouse MAb PB1, specific for hamster 5ß1, was purchased from the Developmental Studies Hybridoma Bank (University of Iowa). MAb PB1 and the murine, anti-type-O FMDV MAbs, C9 (IgG2a) and B2 (IgG1) (34, 57), were purified with protein A (Pierce) according to the manufacturer’s instructions. R-Phycoerythrin-conjugated antibodies were purchased from Southern Biotechnology Associates.

Flow cytometry analysis. (i) Standard assay. Flow cytometry was performed as described previously (36). Briefly, cells were harvested with EDTA and resuspended at 10⁷ cells per ml in Tris-buffered saline (pH 7.4) containing 1 mM CaCl₂, 0.5 mM MgCl₂, 2% normal goat serum, and 3% bovine serum albumin (buffer A). Cells were incubated with primary antibodies (10 µg/ml in buffer A) on ice for 20 min followed by secondary antibodies conjugated with R-phycoerythrin. Background fluorescence was determined in the absence of the primary antibody. Fluorescent staining was analyzed by flow cytometry with a FACSCalibur (Becton Dickinson) counting 6,000 cells per sample.

(ii) Virus binding assay. Cells were prepared in buffer A as above and incubated with purified FMDV O1K-cad² (at the indicated concentration) for 1 h on ice, followed by the anti-FMDV MAb C9 (10 µg/ml) and a goat anti-mouse IgG2a-specific, R-phycoerythrin conjugate. Virus binding in the presence of manganese was carried out as described above using buffer A supplemented with 1 mM MnCl₂ (buffer B). Virus binding in the presence of the activating anti-ß1 antibody (MAb 9EG7; 10 µg/ml) was carried out in buffer B. Background fluorescence was determined under three conditions: in the absence of the virus, in the absence of the anti-FMDV MAb, and by incubating the cells with MAb 9EG7 followed by the goat anti-mouse IgG2a-specific, R-phycoerythrin-conjugated antibody. All conditions gave nearly identical results, which are shown as a single histogram on the figures.

(iii) Competition experiments. For experiments where integrin-specific antibodies or RGD peptides were used to block binding of FMDV, these reagents were added to the cells in duplicate wells for 0.5 h on ice before the addition of virus for a further 0.5 h. Experiments using cells expressing vß1 or the 5/v(F1-G223)/ß1 chimera were carried out in the presence of manganese. Cell-bound virus was detected by using an anti-FMDV MAb as above. When the competing antibody was a mouse IgG2a (e.g., 10D5), virus was detected by using the anti-FMDV MAb B2 (IgG1) followed by a goat anti-mouse IgG1-specific, R-phycoerythrin-conjugated antibody. When the competing antibody was a mouse IgG1 (e.g., L230), virus was detected by using the anti-FMDV MAb C9 (IgG2a) followed by a goat anti-mouse IgG2a-specific, R-phycoerythrin-conjugated antibody. Background fluorescence was determined for each of the competing MAbs separately by incubating cells with the anti-integrin MAb (100 µg/ml), followed by the anti-isotype-specific conjugated antibody used to detect virus binding.

Infectious center assay. (i) Standard assay. Cells were harvested with trypsin, resuspended in cell culture media, and placed at 37°C for 1 h with continuous rotation. One million cells were resuspended in Tris-buffered saline (pH 7.4) containing the divalent cations as indicated on the figures in the presence or absence of MAb 9EG7 and infected with FMDV O1Kcad² or O1BFS (MOI, 0.5) at 37°C for 0.5 h with continuous rotation. Following infection, virus that remained on the outsides of the cells was inactivated by the addition of 1 ml of 0.1 M citric acid buffer (pH 5.2) for 1 min. The cells were washed with PBS (pH 7.5) containing 2 mM CaCl₂ and 1 mM MgCl₂ and resuspended in 300 µl of the same buffer supplemented with 0.5% fetal calf serum. Dilutions of the infected cells (100 µl) were layered onto subconfluent monolayers of BHK cells as previously described (24), and the monolayers were incubated at 37°C for 40 to 48 h. Infectious centers were visualized as plaques by staining with methylene blue-4% formaldehyde in phosphate-buffered saline (pH 7.5).

(ii) Competition experiments. Anti-integrin antibodies and peptides were added to the cells for 0.5 h on ice prior to the addition of virus, and incubation continued on ice for a further 0.5 h. The cells were washed with cold Dulbecco’s minimal essential medium, resuspended in prewarmed cell culture media, and incubated at 37°C for 0.5 h with continuous rotation. Following infection, virus that remained on the outsides of the cells was acid inactivated and the cells were plated onto BHK monolayers as described above.

Top Abstract Introduction Materials and Methods Results Discussion References

 
CHO cells normally express two RGD-binding integrins, vß5 and 5ß1, but are nonpermissive for field strains of FMDV (21, 32, 42, 54). However, CHO cells are susceptible to infection by FMDV strains that have been adapted for growth in cultured cells and use heparan sulfate proteoglycans as receptors without the mediation of integrins (15, 21, 42, 46). These observations indicate that the failure of FMDV field strains to infect CHO cells results from a lack of an appropriate integrin receptor and not from intracellular deficiencies in virus replication. The CHO variant cell line, CHOB2, lacks endogenous 5. When transfected with human v cDNA, these cells differ from wt CHO cells in that they no longer express 5ß1 but do express vß1 (human-v/hamster-ß1) at the cell surface as a functional heterodimer (38, 51, 60). We have used these cells (38) to determine whether vß1 has the ability to serve as a receptor for FMDV, the rationale being that these cells express only two v integrins, vß1 and vß5, and we and others have previously found that vß5 does not appear to mediate infection by FMDV (24, 32, 42). In this study, we compared CHOB2 cells expressing vß1 (CHOB2-vß1) with untransfected cells. CHOB2 cells expressing v/5 chimeras, paired with the endogenous hamster ß1 subunit [v/5(F1-G232)/ß1 and 5/v(F1-G223)/ß1 (see Materials and Methods)] were also included in these investigations. The v/5(F1-G232)/ß1 chimera has a ligand binding specificity identical to that of wt 5ß1 (38) and therefore, like wt 5ß1, would not be expected to mediate FMDV infection, whereas the 5/v(F1-G223)/ß1 chimera has a ligand binding specificity identical to that of wt vß1 (38). These cells have been reported to express the chimeric integrins at a level similar to that of wt vß1 on CHOB2-vß1 (38). We also included CHOB2 cells transfected with the wt human ß6 subunit that express vß6 (CHOB2-vß6) (54). Initially, we confirmed by flow cytometry the reported integrin expression profiles for the above cells by using the anti-integrin antibodies listed in Materials and Methods (data not shown).

Next, we determined whether vß1 expressed on CHOB2 cells could support FMDV binding. Since integrin-ligand interactions are dependent on divalent cations, initial experiments were carried out in the presence of physiological concentrations of calcium (Ca) and magnesium (Mg). Figure 1 shows that when Ca and Mg were the supporting cations, virus binding was not detected with the parental CHOB2 cells or cells expressing the v/5(F1-G232)/ß1 chimera. A small amount of virus binding was observed with cells expressing vß1 and the 5/v(F1-G223)/ß1 chimera, and virus binding to cells expressing vß6 was readily detected.

View larger version (19K): [in this window] [in a new window]

FIG. 1. Flow cytometric analysis of FMDV binding to CHOB2 and integrin-transfected CHOB2 cell lines. FMDV strain O1K-cad2 (20 µg/ml) was bound to CHOB2 (A and B), v/5(F1-G232)/ß1 (C and D), CHOB2-vß1 (E and F), 5/v(F1-G223)/ß1 (G and H), and CHOB2-vß6 (I and J) in the presence of Ca and Mg alone (A, C, E, G, and I) or in the presence of Ca, Mg, and Mn (B, D, F, H, and J). Virus binding (hatched histogram) was determined by using the anti-FMDV MAb C9 and a goat anti-mouse IgG2a-specific R-phycoerythrin conjugate. Background fluorescence (black histogram) was determined as described in Materials and Methods. Virus binding in the presence of the activating anti-ß1-MAb 9EG7 (D, F, and H) is shown as the open histogram. One experiment representative of three is shown.

Since manganese (Mn) ions are known to enhance ligand binding to several integrins (22, 23, 37, 50), we next determined the effect of Mn on virus binding to the integrin-transfected cells. As with Ca and Mg alone, virus binding in the presence of Mn was not detected with untransfected CHOB2 and cells expressing the v/5(F1-G232)/ß1 chimera (Fig. 1). In addition, Mn did not enhance virus binding to cells expressing vß6 over that observed in the presence of Ca and Mg alone. However, addition of Mn dramatically enhanced virus binding to cells expressing wt vß1 and the 5/v(F1-G223)/ß1 chimera (Fig 1). These observations suggest that vß1 is expressed in a low-affinity state on the transfected cells and that integrin activation is required for FMDV binding.

Binding to ß1 integrins can also be enhanced by activating anti-ß1 antibodies (22, 39). We therefore examined the effects of one such antibody, 9EG7 (2), on virus binding. Figure 1 shows that in the presence of 9EG7, virus binding to cells expressing either wt vß1 or the 5/v(F1-G223)/ß1 chimera was further enhanced over that in the presence of Mn, whereas virus binding to cells expressing the v/5(F1-G232)/ß1 chimera was not stimulated by this antibody. These observations confirm that activation of ß1 integrins leads to enhanced binding of FMDV to CHOB2-vß1.

To verify that FMDV was binding to vß1 on the transfected cells, and through an authentic RGD-dependent interaction, we carried out competition experiments with function-blocking anti-integrin MAbs and RGD-containing peptides. Figure 2 shows that virus binding to CHOB2-vß1 cells in the presence of Mn was inhibited by the anti-v MAb L230 but not by the anti-vß5 MAb (P1F6). These data demonstrate that an v integrin is the major site for virus attachment on the vß1-expressing cells and that the endogenous hamster vß5 does not significantly contribute to virus attachment. We were unable to perform competition experiments using a functional blocking MAb for the ß1 subunit since we have not been able to identify such MAbs cross-reactive for hamster ß1. However, given that these cells express vß1 and vß5 as their only RGD-binding integrins (38) and that virus binding was not significantly inhibited by the anti-vß5 MAb which is known to be cross-reactive for hamster vß5 (54), we conclude that vß1 is the major receptor for FMDV attachment on CHOB2-vß1. This conclusion is supported by the fact that the anti-v MAb (L230), which blocks virus binding efficiently, does not recognize the hamster v subunit, implying that the human v in the vß1 population mediated virus binding.

View larger version (12K): [in this window] [in a new window]

FIG. 2. Anti-integrin MAbs inhibit binding of FMDV to CHOB2 cell lines expressing vß1 or vß6. CHOB2-vß1 (A) or CHOB2-vß6 (B) cells were pretreated with the anti-v MAb, L230 (A), the anti-vß6 MAb, 10D5 (B), or the anti-vß5 MAb, P1F6 (A and B), at 100 µg/ml for 0.5 h prior to the addition of virus (O1Kcad2; 20 µg/ml). Virus binding to cells expressing vß1 was carried out in the presence of manganese. Virus binding was detected by flow cytometry as described in Materials and Methods and is expressed as the percentage of virus bound to cells pretreated with assay buffer alone (control). The means from two independent experiments are shown, and in each case the range of observations was within 5% of the mean.

Virus binding to CHOB2-vß1 was also inhibited by RGD-containing peptides (Fig. 3). Both a GRGDSP peptide and a longer RGD peptide (FMDV-RGD), with its sequence derived from the FMDV RGD site (see Materials and Methods), were found to inhibit virus binding in a concentration-dependent manner, whereas the control RGE versions of these peptides had only minimal effects on binding. Virus binding to CHOB2-vß1 in the presence of the activating anti-ß1 MAb 9EG7 was also inhibited by MAb L230 and the RGD peptides but not by MAb P1F6 or the control RGE peptides (data not shown), indicating that following integrin activation, virus binding to these cells was also mediated by vß1. Similarly, virus binding in the presence of Mn to cells expressing the 5/v(F1-G223)/ß1 chimera was also specifically inhibited by these reagents (data not shown).

View larger version (28K): [in this window] [in a new window]

FIG. 3. RGD peptides differentially inhibit FMDV binding to CHOB2 cell lines expressing vß1 or vß6. CHOB2-vß6 (A) or CHOB2-vß1 (B) cells were pretreated with RGD or control RGE peptides at the indicated concentrations for 0.5 h prior to the addition of virus (O1Kcad2; 20 µg/ml). FMDV-RGD (VPNLRGDLQVLA) has its sequence derived from the FMDV RGD site. Virus binding to cells expressing vß1 was carried out in the presence of manganese. Virus binding was detected by flow cytometry as described in Materials and Methods and is expressed as the percentage of virus bound to cells pretreated with assay buffer alone (control). The means from two independent experiments are shown, and in each case the range of observations was within 10% of the mean.

We also compared the abilities of peptides to block vß6. Consistent with our previous observations gleaned from experiments using transfected SW480 cells expressing vß6, FMDV binding to CHOB2 cells expressing vß6 was inhibited by the anti-vß6 MAb (10D5) and the FMDV RGD peptide (FMDV-RGD). However, in contrast to the cells expressing vß1, the short GRGDSP peptide had little or no effect on virus binding to vß6, even when used at high concentrations (Fig. 3). These observations suggest that the residues flanking the RGD tripeptide in the GH loop of VP1 may be required for high-affinity binding to vß6. This observation was not unique to the hamster-v/human-ß6 receptor expressed on CHOB2-vß6 cells since the same observations were made with SW480 cells expressing human vß6 (data not shown).

The above data show that vß1 expressed on transfected CHOB2 cells serves as a receptor for FMDV attachment. Next, we determined whether vß1 could mediate infection using an infectious center assay. Table 1 shows that for parental CHOB2 or cells expressing the v/5(F1-G232)/ß1 chimera, only a small number of infectious centers resulted from infection in the presence of Ca and Mg compared to the number observed for cells infected at 4°C. In addition, Table 1 shows that, consistent with the observation that Mn ions did not enhance virus binding, infection of these cells was not significantly enhanced by the addition of Mn. In contrast, infection of cells expressing wt vß1 or the 5/v(F1-G223)/ß1 chimera resulted in substantially (60 times) more infectious centers than those obtained with the parental CHOB2 cells (Table 1). Furthermore, upon integrin activation, either by Mn ions or by the activating anti-ß1 MAb (9EG7), the number of infectious centers observed for these cells was further increased (380 or 950 times, respectively) over the number obtained with untransfected cells. Consistent with the observation that Mn ions did not enhance virus binding to vß6 (Fig. 1), infection of the CHOB2-vß6 cell line in the presence of Mn was not enhanced over that in the presence of Ca and Mg alone (Table 1). Table 1 also shows that CHOB2 cells are permissive for a heparan sulfate-binding strain of FMDV (O1BFS), indicating that as for wt CHO cells, the failure of CHOB2 cells to support infection by field strains of FMDV does not result from intracellular deficiencies in virus replication.

View this table: [in this window] [in a new window]

TABLE 1. FMDV infection of integrin-transfected CHOB2 cell lines

Figures 4 and 5 show that the inhibitory effects of the anti-v MAb (L230) and the RGD-containing peptides on infection correlated with the ability of these reagents to inhibit virus binding to vß1. Thus, in the presence of Ca, Mg, and Mn, the anti-v MAb (Fig. 4) and the RGD-containing peptides (Fig. 5) were found to specifically inhibit infection of CHOB2-vß1. Similarly, infection of these cells in Ca and Mg alone, or in the presence of MAb 9EG7, and infection of cells expressing the 5/v-ß1 chimera in the presence of Ca, Mg, and Mn were also inhibited by MAb L230 and the RGD peptides but not by the anti-vß5 MAb P1F6 or the RGE control peptides (data not shown). Figure 4 also shows that infection of CHOB2-vß6 was inhibited by the anti-vß6 MAb 10D5 but, again, not by P1F6 (ant-vß5). Consistent with the observation that the GRGDSP peptide was ineffective at inhibiting virus binding to vß6, this reagent did not significantly inhibit infection of CHOB2-vß6 cells under conditions where the FMDV-derived peptide (FMDV-RGD) inhibited infection in a concentration-dependent manner (Fig. 5).

View larger version (13K): [in this window] [in a new window]

FIG. 4. Infection of integrin-transfected CHOB2 cells is inhibited by anti-integrin antibodies. Duplicate aliquots of CHOB2-vß1 (A) or CHO-vß6 (B) cells were pretreated with the anti-v MAb (L230) (A), the anti-vß6 MAb (10D5) (B), or the anti-vß5 MAb (P1F6) (A and B) at 50 µg/ml for 0.5 h prior to the addition of cold virus (O1Kcad2) at a MOI of 1 PFU/cell for a further 0.5 h. The cells were washed to remove unbound virus, and infection was initiated by incubation at 37°C for 0.5 h. Virus that remained on the outsides of the cells was acid inactivated, and the infected cells were used in an infectious center assay. The infection of cells expressing vß1 was carried out in the presence of manganese. Control samples were incubated with assay buffer alone (control) before the addition of virus. The means from two independent experiments are shown, and in each case the range of observations was within 5% of the mean.

View larger version (23K): [in this window] [in a new window]

FIG. 5. Infection of integrin-transfected CHOB2 cells is inhibited by RGD peptides. Duplicate cell aliquots of CHOB2-vß1 (A) or CHO-vß6 (B) were pretreated with RGD peptides at the indicated concentrations for 0.5 h prior to the addition of cold virus (O1Kcad2) at a MOI of 1 PFU/cell for a further 0.5 h. The cells were then treated as described for Fig. 4. Infection of cells expressing vß1 was carried out in the presence of manganese. Control samples were incubated with assay buffer alone (control) before the addition of virus. The means from two independent experiments are shown, and in each case the range of observations was within 10% of the mean.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Several viruses have been reported to utilize multiple RGD-dependent integrins to initiate infection (see the introduction). Prior to these studies, FMDV was reported to use two v integrins, vß3 and vß6, as cellular receptors (4, 24). In this study we show that another v-integrin, vß1, also serves as a receptor for FMDV. The main pieces of evidence in support of this finding are as follows. (i) CHOB2 cells, which are normally nonpermissive for field strains of FMDV, become susceptible to infection upon transfection with the integrin v-subunit and expression of vß1 at the cell surface. (ii) vß1 serves as the major receptor for virus attachment on the transfected cells, since virus binding is inhibited >98% by a function-blocking MAb that specifically recognizes human v. (iii) Consistent with the above observations, infection of the transfected cells is also inhibited >98% by the same antibody. In addition, RGD-containing peptides were shown to specifically inhibit virus attachment and infection mediated by vß1. Consistent with these data, we found that an 5/v-ß1 chimera (5/v(F1-G223)/ß1), which has a ligand binding specificity identical to that of wt vß1, also binds and mediates infection by FMDV, thus providing further evidence for the receptor role of vß1. In contrast, an 5/v-ß1 chimera (v/5(F1-G232)/ß1) with a ligand binding specificity identical to that of wt 5ß1 did not support either of these processes, consistent with the observation that 5ß1 does not mediate infection by FMDV (24, 32, 42). While these studies were in progress, the crystal structure of the extracellular domains of vß3 was reported (58) and reveals that the putative RGD-binding site includes loop regions that lie within residues 1 to 223 of the v chain, consistent with the results of the present study.

An important finding of our studies is that in the presence of physiological concentrations of Ca and Mg, FMDV binding and infection mediated by vß1 are relatively inefficient; however, following integrin activation by Mn or an activating anti-ß1 antibody, the ability of vß1 to function as a receptor for FMDV is dramatically enhanced. Our data with FMDV are consistent with binding of the natural ligands of vß1, which is known to be differentially regulated by divalent cations. Thus, Mn and Mg, but not Ca, support ligand binding and Ca abolishes Mg-promoted adhesion (5, 25, 31, 40, 53). Moreover, activation by an activating anti-ß1 MAb similar to that used in the present study overrides the inhibitory effect of Ca on binding of osteopontin to vß1 (18). In contrast to vß1, vß6 on transfected CHOB2 cells appeared to be expressed in a high-affinity state, since neither virus binding nor infection was enhanced by Mn, suggesting that different molecular mechanisms regulate the affinities of vß1 and vß6 for FMDV.

The number of infectious centers obtained with cells expressing vß6 was significantly greater than the number obtained with cells expressing vß1 (Table 1). Since vß1 (human-v/hamster-ß1) and vß6 (hamster-v/human-ß6) expressed on the transfected cells do not share a common subunit, we have not been able to reliably determine the relative level of expression of the transfected integrins. However, some clues regarding the relative efficiency of vß1 and vß6 at mediating infection by FMDV can be gained by comparing the amount of virus binding with the level of infection. The number of infectious centers obtained with cells expressing vß6 was approximately eight times greater than with cells expressing vß1, even though the two sets of cells bound similar amounts of virus (Table 1 and Fig. 1). These data suggest that virus bound to vß6 may be internalized more efficiently than virus bound to vß1.

A short RGD-containing peptide (GRGDSP) and a longer peptide with a sequence derived from the RGD site of FMDV were found to inhibit virus binding and infection mediated by vß1. We have previously observed that these peptides also inhibit FMDV binding to purified vß3 in vitro (23) and for both vß1 and vß3, the GRGDSP peptide was the more potent inhibitor. In the present study, we observed that under conditions where the FMDV peptide inhibited virus binding and infection mediated by vß6, the GRGDSP peptide was largely ineffective. These observations suggest that residues that flank the RGD tripeptide of FMDV may be required for high-affinity ligand binding to vß6. In addition to binding vß1, LAP-1 has recently been identified as a high-affinity ligand for vß6 (41). As was reported previously, FMDV (RGDLXXL) and LAP-1 (RGDLXXI) share a sequence similarity at the residues following the RGD (22, 24). Given this similarity, and given furthermore that a pentapeptide (DLXXL) with a sequence similar to the residues following the FMDV RGD site has recently been shown to inhibit ligand binding to vß6 (26), it is interesting to speculate that the conserved leucine residues located at the RGD + 1 and RGD + 4 positions in FMDV may be required for virus binding to vß6.

An important question that has yet to be addressed concerns the roles of the various integrin receptors in the pathogenesis of FMDV. FMDV has a strong predisposition for epithelial cells (1, 8, 9, 10, 47, 59). The primary site of virus replication is thought to be the epithelial cells of the upper respiratory tract. During the development of disease, virus is widely disseminated throughout the body, with secondary sites of replication in many epithelial tissues (1, 10, 59). Currently, no information exists regarding integrin expression in the upper respiratory tract of the natural hosts of FMDV. However, studies with other species have shown that vß6 and multiple ß1 integrins, but not vß3, are expressed on mucosal epithelium (6, 7, 12, 17, 35), suggesting that vß6 may have a prominent role in infection at these sites. Little is known about the in vivo cell type expression or tissue distribution of vß1 since no complex specific antibodies are currently available. We therefore cannot be certain what role, if any, vß1 might play in in vivo infections with FMDV. Nonetheless, the results of the present study suggest that the ability of FMDV to infect vß1-expressing cells is likely to be highly regulated by the cellular mechanisms that modulate the ligand-binding affinity of ß1 integrins.

 
We thank M. Pitkeathly and S. Shah for the peptides.

This work was supported by DEFRA.

 
* Corresponding author. Mailing address: Pirbright Laboratory, Institute for Animal Health, Ash Rd., Pirbright, Surrey GU24 ONF, United Kingdom. Phone: 44-1483-232441. Fax: 44-1483-237161. E-mail: terry.jackson{at}bbsrc.ac.uk.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Alexandersen, A., M. B. Oleksiewicz, and A. I. Donaldson. 2001. The early pathogenesis of foot-and-mouth disease virus in pigs infected by contact: a quantitative time-course study using TaqMan RT-PCR. J. Gen. Virol. 82:747–755.[Abstract/Free Full Text]
2
2. Bazzoni, G. N., D. Shih, C. A. Buck, and M. E. Hemler. 1995. Monoclonal antibody 9EG7 defines a novel ß1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270:25570–25577.[Abstract/Free Full Text]
3
3. Belsham, G. J. 1993. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family: aspects of virus protein synthesis, protein processing and structure. Prog. Biophys. Mol. Biol. 69:241–260.
4
4. Berinstein, A., M. Roivainen, T. Hovi, P. W. Mason, and B. Baxt. 1995. Antibodies to the vitronectin receptor (integrin vß3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J. Virol. 69:2664–2666.[Abstract]
5
5. Bodary, S. C., and J. W. McLean. 1990. The integrin ß1 subunit associates with the vitronectin receptor v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J. Biol. Chem. 265:5938–5941.[Abstract/Free Full Text]
6
6. Breuss, J. M., J. Gallo, H. M. DeLisser, I. V. Kilmanskaya, H. G. Folkesson, J. F. Pittet, S. L. Nishimura, K. Aldape, D. V. Landers, W. Carpenter, N. Gillett, D. Sheppard, M. A. Matthay, S. M. Albelda, R. H. Krammer, and R. Pytela. 1995. Expression of the ß6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodelling. J. Cell Sci. 108:2241–2251.[Abstract]
7
7. Breuss, J. M., N. Gillett, L. Lu, D. Sheppard, and R. Pytela. 1993. Restricted distribution of integrin ß6 messenger RNA in primate epithelial tissues. J. Histochem. Cytochem. 41:1521–1527.[Abstract]
8
8. Brown, C. C., R. F. Meyer, H. J. Olander, C. House, and C. A. Mebus. 1992. A pathogenesis study of foot-and-mouth disease virus in cattle, using in situ hybridisation. Can. J. Vet. Res. 56:189–193.[Medline]
9
9. Brown, C. C., H. J. Olander, and R. F. Meyer. 1991. A preliminary study of the pathogenesis of foot-and-mouth disease virus, using in situ hybridisation. Vet. Pathol. 28:216–222.[Abstract]
10
10. Burrows, R., J. A. Mann, A. J. M. Garland, A. Greig, and D. Goodridge. 1981. The pathogenesis of natural and stimulated natural foot-and-mouth disease virus infection in cattle. J. Comp. Pathol. 91:599–609.[CrossRef][Medline]
11
11. Curry, S., E. Fry, W. E. Blakemore, R. Abu-Ghazaleh, T. Jackson, A. King, S. Lea, J. Newman, D. Rowlands, and D. Stuart. 1996. Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Structure 4:135–145.[Medline]
12
12. Damjanovich, L., S. M. Albelda, S. A. Mette, and C. A. Buck. 1992. Distribution of integrin cell adhesion receptors in normal and malignant lung tissue. Am. J. Respir. Cell Mol. Biol. 6:197–206.
13
13. Davison, E., R. M. Diaz, I. R. Hart, G. Santis, and J. F. Marshall. 1997. Integrin 5ß1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J. Virol. 71:6204–6207.[Abstract]
14
14. Dedhar, S., and G. E. Hannigan. 1996. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr. Opin. Cell Biol. 8:657–669.[CrossRef][Medline]
15
15. Fry, E., S. M. Lea, T. Jackson, J. W. I. Newman, F. M. Ellard, W. E. Blakemore, R. Abu-Ghazaleh, A. Samuel, A. M. Q. King, and D. I. Stuart. 1999. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18:543–554.[CrossRef][Medline]
16
16. Giancotti, F. G., and E. Ruoslahtil. 1999. Integrin signalling. Science 285:1028–1032.[Abstract/Free Full Text]
17
17. Haapasalmi, K., K. Zhang, M. Tonnesen, J. Olerud, D. Sheppard, T. Salo, R. Krammer, R. Clark, V. Uitto, and H. Larjava. 1996. Keratinocytes in human wounds express alpha v beta 6 integrin. J. Investig. Dermatol. 106:42–48.[CrossRef][Medline]
18
18. Hu, D. D., E. C. K. Lin, N. L. Kovach, J. R. Hoyer, and J. W. Smith. 1995. A biochemical characterization of the binding of osteopontin to integrins vß1 and vß5. J. Biol. Chem. 270:26232–26238.[Abstract/Free Full Text]
19
19. Hughes, P. E., M. W. Renshaw, M. Pfaff, J. Forsyth, V. M. Keivens, M. A. Schwartz, and M. H. Ginsberg. 1997. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88:521–530.[CrossRef][Medline]
20
20. Hynes, R. O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11–25.[CrossRef][Medline]
21
21. Jackson, T., F. M. Ellard, R. Abu-Ghazaleh, S. M. Brookes, W. E. Blakemore, A. H. Corteyn, D. I. Stuart, J. W. I. Newman, and A. M. Q. King. 1996. Efficient infection of cells in culture by type O foot-and mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282–5287.[Abstract/Free Full Text]
22
22. Jackson, T., W. E. Blakemore, J. W. I. Newman, N. J. Knowles, A. P. Mould, M. J. Humphries, and A. M. Q. King. 2000. Foot-and mouth disease virus is a ligand for the high-affinity binding conformation of integrin 5ß1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding. J. Gen. Virol. 81:1383–1391.[Abstract/Free Full Text]
23
23. Jackson, T., A. Sharma, R. Abu-Ghazaleh, W. E. Blakemore, F. M. Ellard, D. L. Simmons, J. W. I. Newman, D. I. Stuart, and A. M. Q. King. 1997. Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease virus to the purified integrin vß3 in vitro. J. Virol. 71:8357–8361.[Abstract]
24
24. Jackson, T., D. Sheppard, M. Denyer, W. E. Blakemore, and A. M. Q. King. 2000. The epithelial integrin vß6 is a receptor for foot-and-mouth disease virus. J. Virol. 74:4949–4956.[Abstract/Free Full Text]
25
25. Kirchhofer, D., J. Grzesiak, and M. D. Pierschbacher. 1991. Calcium as a potential physiological regulator of integrin-mediated cell adhesion. J. Biol. Chem. 266:4471–4477.[Abstract/Free Full Text]
26
26. Kraft, S., B. Diefenbach, R. Mehta, A. Jonczyk, A. Luckenbach, and S. L. Goodman. 1999. Definition of an unexpected ligand recognition motif for vß6 integrin. J. Biol. Chem. 274:1979–1985.[Abstract/Free Full Text]
27
27. Lee, J. O., L. A. Bankston, M. A. Arnaout, and R. C. Liddington. 1995. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 3:1333–1340.[Medline]
28
28. Li, E., S. L. Brown, D. G. Stupack, X. S. Puente, D. A. Cheresh, and G. R. Nemerow. 2001. Integrin vß1 is an adenovirus coreceptor. J. Virol. 75:5405–5409.[Abstract/Free Full Text]
29
29. Li, R., P. Rieu, D. L. Griffith, D. Scott, and M. A. Arnaout. 1998. Two functional states of the CD11b A-domain: correlations with key features of two Mn²⁺-complexed crystal structures. J. Cell Biol. 143:1523–1534.[Abstract/Free Full Text]
30
30. Logan, D., R. Abu-Ghazaleh, W. E. Blakemore, S. Curry, T. Jackson, A. King, S. Lea, R. Lewis, J. W. I. Newman, N. Parry, D. Rowlands, D. Stuart, and E. Fry. 1993. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362:566–568.[CrossRef][Medline]
31
31. Marshall, J. F., D. C. Rutherford, A. C. E. McCartney, F. Mitjans, S. L. Goodman, and I. R. Hart. 1995. vß1 is a receptor for vitronectin and fibronectin, and acts with 5ß1 to mediate spreading on fibronectin. J. Cell Sci. 108:1227–1238.[Abstract]
32
32. Mason, P. W., B. Baxt, F. Brown, J. Harber, A. Murdin, and E. Wimmer. 1993. Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect cells via the Fc receptor. Virology 192:568–577.[CrossRef][Medline]
33
33. Mason, P. W., E. Rieder, and B. Baxt. 1994. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc. Natl. Acad. Sci. USA 91:1932–1936.[Abstract/Free Full Text]
34
34. McCahon, D., J. R. Crowther, G. J. Belsham, J. D. A. Kitson, M. Duchesne, P. Have, R. H. Meloen, D. O. Morgan, and F. de Simone. 1989. Evidence for at least 4 antigenic sites on type foot-and-mouth disease virus involved in neutralization; identification by single and multiple monoclonal antibody-resistant mutants. J. Gen. Virol. 70:639–645.[Abstract/Free Full Text]
35
35. Mette, S. A., J. Pilewski, C. A. Buck, and S. M. Albelda. 1993. Distribution of integrin cell adhesion receptors in normal bronchial epithelial cells and lung cancer cells in vitro and in vivo. Am. J. Respir. Cell Mol. Biol. 8:562–572.
36
36. Miller, L. C., W. E. Blakemore, D. Sheppard, A. Atakilit, A. M. Q. King, and T. Jackson. 2001. Role of the cytoplasmic domain of the ß-subunit of integrin vß6 in infection by foot-and mouth disease virus. J. Virol. 75:4158–4164.[Abstract/Free Full Text]
37
37. Mould, A. P., S. K. Akiyama, and M. J. Humphries. 1995. Regulation of integrin 5ß1-fibronectin interactions by divalent cations. J. Biol. Chem. 270:26270–26277.[Abstract/Free Full Text]
38
38. Mould, A. P., J. A. Askari, and M. J. Humphries. 2000. Molecular recognition by integrin 5ß1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH₂-terminal repeats of the a subunit. J. Biol. Chem. 275:20324–20336.[Abstract/Free Full Text]
39
39. Mould, A. P., A. N. Garratt, J. A. Askari, S. K. Akiyama, and M. J. Humphries. 1995. Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the ß1 subunit. FEBS Lett. 363:118–122.[CrossRef][Medline]
40
40. Munger, J. S., J. G. Harpel, F. G. Giancotti, and D. B. Rifkin. 1998. Interactions between growth factors and integrins: latent forms of transforming growth factor-ß are ligands for the integrin vß1. Mol. Biol. Cell 9:2627–2638.[Abstract/Free Full Text]
41
41. Munger, J. S., X. Huang, H. Kawakatsu, M. D. J. Griffiths, S. L. Dalton, J. Wu, J. F. Pittet, N. Kaminski, C. Garat, M. A. Matthay, D. B. Rifkin, and D. Sheppard. 1999. The integrin vß6 binds and activates latent TGFß1:a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319–328.[CrossRef][Medline]
42
42. Neff, S., D. Sa-Carvalho, E. Rieder, P. W. Mason, S. D. Blystone, E. J. Brown, and B. Baxt. 1998. Foot-and-mouth disease virus virulent for cattle utilizes the integrin vß3 as its receptor. J. Virol. 72:3587–3594.[Abstract/Free Full Text]
43
43. Nelsen-Salz, B., H. J. Eggers, and H. Zimmermann. 1999. Integrin vß3 (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty. J. Gen. Virol. 80:2311–2313.[Abstract/Free Full Text]
44
44. Pulli, T., E. Koivunen, and T. Hyypiä. 1997. Cell-surface interactions of echovirus 22. J. Biol. Chem. 272:21176–21180.[Abstract/Free Full Text]
45
45. Roivainen, M., L. Piirainen, T. Hovi, I. Virtanen, T. Riikonen, J. Heino, and T. Hyypiä. 1994. Entry of coxsackievirus A9 into host cells: specific interactions with vß3 integrin, the vitronectin receptor. Virology 203:357–365.[CrossRef][Medline]
46
46. Sa-Carvalho, D., E. Rieder, B. Baxt, R. Rodarte, A. Tanuri, and P. W. Mason. 1997. Tissue culture adaption of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115–5123.[Abstract]
47
47. Salt, J. S. 1998. Persistent infection with foot-and-mouth disease virus. Top. Trop. Virol. 1:77–129.
48
48. Schreiner, C. L., J. S. Bauer, N. Y. Danilov, S. Hussein, M. Sczekan, and R. L. Juliano. 1989. Isolation and characterization of Chinese hamster ovary cell variants deficient in the expression of the fibronectin receptor. J. Cell Biol. 109:3157–3167.[Abstract/Free Full Text]
49
49. Sheppard, D., D. S. Cohen, A. Wang, and M. Busk. 1992. Transforming growth factor ß differentially regulates expression of integrin subunits in a guinea pig airway epithelial cells. J. Biol. Chem. 267:17409–17414.[Abstract/Free Full Text]
50
50. Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 346:425–447.[CrossRef][Medline]
51
51. Takagi, J., T. Kamata, J. Meredith, W. Puzon-McLaughlin, and Y. Takada. 1997. Changing ligand binding specificities of vß1 and vß3 integrins by swapping a short diverse sequence of the ß subunit. J. Biol. Chem. 272:19794–19800.[Abstract/Free Full Text]
52
52. Triantafilou, K., M. Triantafilou, Y. Takada, and N. Fernandez. 2000. Human parechovirus 1 utilizes integrin vß3 and vß1 as receptors. J. Virol. 74:5856–5862.[Abstract/Free Full Text]
53
53. Vogel, B. E., G. Tarone, F. G. Giancotti, J. Gailit, and E. Ruoslahti. 1990. A novel fibronectin receptor with an unexpected subunit composition (vß1). J. Biol. Chem. 265:5934–5937.[Abstract/Free Full Text]
54
54. Weinacker, A., A. Chen, M. Agrez, R. I. Cone, S. Nishimura, E. Wayner, R. Pytela, and D. Sheppard. 1994. Role of the integrin vß6 in cell attachment to fibronectin. J. Biol. Chem. 269:6940–6948.[Abstract/Free Full Text]
55
55. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins vß3 and vß5 promote adenovirus internalization but not virus attachment. Cell 73:309–319.[CrossRef][Medline]
56
56. Wickham, T. J., E. J. Filardo, D. A. Cheresh, and G. R. Nemerow. 1994. Integrin vß5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 127:257–264.[Abstract/Free Full Text]
57
57. Xie, Q.-C., D. McCahon, J. R. Crowther, G. J. Belsham, and K. C. McCullough. 1987. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three antigenic sites. J. Gen. Virol. 68:1637–1647.[Abstract/Free Full Text]
58
58. Xiong, J.-P., T. Stehle, B. Diefenbach, R. Zhang, R. Dunker, D. L. Scott, A. Joachimiak, S. L. Goodman, and A. M. Arnaout. 2001. Crystal structure of the extracellular segment of integrin vß3. Science 294:339–345.[Abstract/Free Full Text]
59
59. Zhang, Z., and P. Kitching. 2000. The localization of persistent foot-and-mouth disease virus in the epithelial cells of the soft palate and pharynx. J. Comp. Pathol. 124:89–94.
60
60. Zhang, Z., A. O. Morla, K. Vuori, J. S. Bauer, R. L. Juliano, and E. Ruoslahti. 1993. The vß1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J. Cell Biol. 122:235–242.[Abstract/Free Full Text]
61
61. Zhang, Z., K. Vuori, H. Wang, J. C. Reed, and E. Ruoslahti. 1996. Integrin activation by R-ras. Cell 85:61–69.[CrossRef][Medline]

---

Journal of Virology, February 2002, p. 935-941, Vol. 76, No. 3
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.3.935-941.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Goodwin, S., Tuthill, T. J., Arias, A., Killington, R. A., Rowlands, D. J. (2009). Foot-and-Mouth Disease Virus Assembly: Processing of Recombinant Capsid Precursor by Exogenous Protease Induces Self-Assembly of Pentamers In Vitro in a Myristoylation-Dependent Manner. J. Virol. 83: 11275-11282 [Abstract] [Full Text]  
• Johns, H. L., Berryman, S., Monaghan, P., Belsham, G. J., Jackson, T. (2009). A Dominant-Negative Mutant of rab5 Inhibits Infection of Cells by Foot-and-Mouth Disease Virus: Implications for Virus Entry. J. Virol. 83: 6247-6256 [Abstract] [Full Text]  
• Cseke, G., Maginnis, M. S., Cox, R. G., Tollefson, S. J., Podsiad, A. B., Wright, D. W., Dermody, T. S., Williams, J. V. (2009). Integrin {alpha}v{beta}1 promotes infection by human metapneumovirus. Proc. Natl. Acad. Sci. USA 106: 1566-1571 [Abstract] [Full Text]  
• Veettil, M. V., Sadagopan, S., Sharma-Walia, N., Wang, F.-Z., Raghu, H., Varga, L., Chandran, B. (2008). Kaposi's Sarcoma-Associated Herpesvirus Forms a Multimolecular Complex of Integrins ({alpha}V{beta}5, {alpha}V{beta}3, and {alpha}3{beta}1) and CD98-xCT during Infection of Human Dermal Microvascular Endothelial Cells, and CD98-xCT Is Essential for the Postentry Stage of Infection. J. Virol. 82: 12126-12144 [Abstract] [Full Text]  
• Gutierrez-Rivas, M., Pulido, M. R., Baranowski, E., Sobrino, F., Saiz, M. (2008). Tolerance to mutations in the foot-and-mouth disease virus integrin-binding RGD region is different in cultured cells and in vivo and depends on the capsid sequence context. J. Gen. Virol. 89: 2531-2539 [Abstract] [Full Text]  
• O'Donnell, V., LaRocco, M., Baxt, B. (2008). Heparan Sulfate-Binding Foot-and-Mouth Disease Virus Enters Cells via Caveola-Mediated Endocytosis. J. Virol. 82: 9075-9085 [Abstract] [Full Text]  
• Harwood, L. J., Gerber, H., Sobrino, F., Summerfield, A., McCullough, K. C. (2008). Dendritic Cell Internalization of Foot-and-Mouth Disease Virus: Influence of Heparan Sulfate Binding on Virus Uptake and Induction of the Immune Response. J. Virol. 82: 6379-6394 [Abstract] [Full Text]  
• DiCara, D., Burman, A., Clark, S., Berryman, S., Howard, M. J., Hart, I. R., Marshall, J. F., Jackson, T. (2008). Foot-and-Mouth Disease Virus Forms a Highly Stable, EDTA-Resistant Complex with Its Principal Receptor, Integrin {alpha}v 6: Implications for Infectiousness. J. Virol. 82: 1537-1546 [Abstract] [Full Text]  
• Gulbahar, M. Y., Davis, W. C., Guvenc, T., Yarim, M., Parlak, U., Kabak, Y. B. (2007). Myocarditis Associated with Foot-and-Mouth Disease Virus Type O in Lambs. Vet Pathol 44: 589-599 [Abstract] [Full Text]  
• Nunez, J. I., Molina, N., Baranowski, E., Domingo, E., Clark, S., Burman, A., Berryman, S., Jackson, T., Sobrino, F. (2007). Guinea Pig-Adapted Foot-and-Mouth Disease Virus with Altered Receptor Recognition Can Productively Infect a Natural Host. J. Virol. 81: 8497-8506 [Abstract] [Full Text]  
• Elayadi, A. N., Samli, K. N., Prudkin, L., Liu, Y.-H., Bian, A., Xie, X.-J., Wistuba, I. I., Roth, J. A., McGuire, M. J., Brown, K. C. (2007). A Peptide Selected by Biopanning Identifies the Integrin {alpha}v{beta}6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer. Cancer Res. 67: 5889-5895 [Abstract] [Full Text]  
• Burman, A., Clark, S., Abrescia, N. G. A., Fry, E. E., Stuart, D. I., Jackson, T. (2006). Specificity of the VP1 GH Loop of Foot-and-Mouth Disease Virus for {alpha}v Integrins. J. Virol. 80: 9798-9810 [Abstract] [Full Text]  
• Pellinen, T., Ivaska, J. (2006). Integrin traffic.. J. Cell Sci. 119: 3723-3731 [Abstract] [Full Text]  
• Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J. (2006). Adeno-Associated Virus Type 2 Contains an Integrin {alpha}5{beta}1 Binding Domain Essential for Viral Cell Entry.. J. Virol. 80: 8961-8969 [Abstract] [Full Text]  
• Brown, J. K., McAleese, S. M., Thornton, E. M., Pate, J. A., Schock, A., Macrae, A. I., Scott, P. R., Miller, H. R.P., Collie, D. D.S. (2006). Integrin-{alpha}v{beta}6, a Putative Receptor for Foot-and-Mouth Disease Virus, Is Constitutively Expressed in Ruminant Airways. J. Histochem. Cytochem. 54: 807-816 [Abstract] [Full Text]  
• Maginnis, M. S., Forrest, J. C., Kopecky-Bromberg, S. A., Dickeson, S. K., Santoro, S. A., Zutter, M. M., Nemerow, G. R., Bergelson, J. M., Dermody, T. S. (2006). {beta}1 Integrin Mediates Internalization of Mammalian Reovirus. J. Virol. 80: 2760-2770 [Abstract] [Full Text]  
• Rieder, E., Henry, T., Duque, H., Baxt, B. (2005). Analysis of a Foot-and-Mouth Disease Virus Type A24 Isolate Containing an SGD Receptor Recognition Site In Vitro and Its Pathogenesis in Cattle. J. Virol. 79: 12989-12998 [Abstract] [Full Text]  
• Monaghan, P., Gold, S., Simpson, J., Zhang, Z., Weinreb, P. H., Violette, S. M., Alexandersen, S., Jackson, T. (2005). The {alpha}v{beta}6 integrin receptor for Foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle. J. Gen. Virol. 86: 2769-2780 [Abstract] [Full Text]  
• Ostrowski, M., Vermeulen, M., Zabal, O., Geffner, J. R., Sadir, A. M., Lopez, O. J. (2005). Impairment of Thymus-Dependent Responses by Murine Dendritic Cells Infected with Foot-and-Mouth Disease Virus. J. Immunol. 175: 3971-3979 [Abstract] [Full Text]  
• Fry, E. E., Newman, J. W. I., Curry, S., Najjam, S., Jackson, T., Blakemore, W., Lea, S. M., Miller, L., Burman, A., King, A. M. Q., Stuart, D. I. (2005). Structure of Foot-and-mouth disease virus serotype A1061 alone and complexed with oligosaccharide receptor: receptor conservation in the face of antigenic variation. J. Gen. Virol. 86: 1909-1920 [Abstract] [Full Text]  
• O'Donnell, V., LaRocco, M., Duque, H., Baxt, B. (2005). Analysis of Foot-and-Mouth Disease Virus Internalization Events in Cultured Cells. J. Virol. 79: 8506-8518 [Abstract] [Full Text]  
• Berryman, S., Clark, S., Monaghan, P., Jackson, T. (2005). Early Events in Integrin {alpha}v{beta}6-Mediated Cell Entry of Foot-and-Mouth Disease Virus. J. Virol. 79: 8519-8534 [Abstract] [Full Text]  
• Monaghan, P., Simpson, J., Murphy, C., Durand, S., Quan, M., Alexandersen, S. (2005). Use of Confocal Immunofluorescence Microscopy To Localize Viral Nonstructural Proteins and Potential Sites of Replication in Pigs Experimentally Infected with Foot-and-Mouth Disease Virus. J. Virol. 79: 6410-6418 [Abstract] [Full Text]  
• Peng, J.-M., Liang, S.-M., Liang, C.-M. (2004). VP1 of Foot-and-Mouth Disease Virus Induces Apoptosis via the Akt Signaling Pathway. J. Biol. Chem. 279: 52168-52174 [Abstract] [Full Text]  
• Duque, H., LaRocco, M., Golde, W. T., Baxt, B. (2004). Interactions of Foot-and-Mouth Disease Virus with Soluble Bovine {alpha}V{beta}3 and {alpha}V{beta}6 Integrins. J. Virol. 78: 9773-9781 [Abstract] [Full Text]  
• Stevenson, R. A., Huang, J.-a., Studdert, M. J., Hartley, C. A. (2004). Sialic acid acts as a receptor for equine rhinitis A virus binding and infection. J. Gen. Virol. 85: 2535-2543 [Abstract] [Full Text]  
• Williams, C. H., Kajander, T., Hyypia, T., Jackson, T., Sheppard, D., Stanway, G. (2004). Integrin {alpha}v{beta}6 Is an RGD-Dependent Receptor for Coxsackievirus A9. J. Virol. 78: 6967-6973 [Abstract] [Full Text]  
• Jackson, T., Clark, S., Berryman, S., Burman, A., Cambier, S., Mu, D., Nishimura, S., King, A. M. Q. (2004). Integrin {alpha}v{beta}8 Functions as a Receptor for Foot-and-Mouth Disease Virus: Role of the {beta}-Chain Cytodomain in Integrin-Mediated Infection. J. Virol. 78: 4533-4540 [Abstract] [Full Text]  
• Grubman, M. J., Baxt, B. (2004). Foot-and-Mouth Disease. Clin. Microbiol. Rev. 17: 465-493 [Abstract] [Full Text]  
• Salone, B., Martina, Y., Piersanti, S., Cundari, E., Cherubini, G., Franqueville, L., Failla, C. M., Boulanger, P., Saggio, I. (2003). Integrin {alpha}3{beta}1 Is an Alternative Cellular Receptor for Adenovirus Serotype 5. J. Virol. 77: 13448-13454 [Abstract] [Full Text]  
• Baranowski, E., Molina, N., Nunez, J. I., Sobrino, F., Saiz, M. (2003). Recovery of Infectious Foot-and-Mouth Disease Virus from Suckling Mice after Direct Inoculation with In Vitro-Transcribed RNA. J. Virol. 77: 11290-11295 [Abstract] [Full Text]  
• SHEPPARD, D. (2003). Functions of Pulmonary Epithelial Integrins: From Development to Disease. Physiol. Rev. 83: 673-686 [Abstract] [Full Text]  
• Zhao, Q., Pacheco, J. M., Mason, P. W. (2003). Evaluation of Genetically Engineered Derivatives of a Chinese Strain of Foot-and-Mouth Disease Virus Reveals a Novel Cell-Binding Site Which Functions in Cell Culture and in Animals. J. Virol. 77: 3269-3280 [Abstract] [Full Text]  
• Duque, H., Baxt, B. (2003). Foot-and-Mouth Disease Virus Receptors: Comparison of Bovine {alpha}V Integrin Utilization by Type A and O Viruses. J. Virol. 77: 2500-2511 [Abstract] [Full Text]  
• Tami, C., Taboga, O., Berinstein, A., Nunez, J. I., Palma, E. L., Domingo, E., Sobrino, F., Carrillo, E. (2002). Evidence of the Coevolution of Antigenicity and Host Cell Tropism of Foot-and-Mouth Disease Virus In Vivo. J. Virol. 77: 1219-1226 [Abstract] [Full Text]  
• Reddi, H. V., Lipton, H. L. (2002). Heparan Sulfate Mediates Infection of High-Neurovirulence Theiler's Viruses. J. Virol. 76: 8400-8407 [Abstract] [Full Text]  
• Koistinen, P., Heino, J. (2002). The Selective Regulation of alpha Vbeta 1 Integrin Expression Is Based on the Hierarchical Formation of alpha V-containing Heterodimers. J. Biol. Chem. 277: 24835-24841 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, T. Articles by King, A. M. Q. Search for Related Content PubMed PubMed Citation Articles by Jackson, T. Articles by King, A. M. Q.